TABLE 2.
Basic characteristics of included studies.
| Author/year/country | Study design | Stent type | Experimental VS. control group | Anticoagulation time |
|---|---|---|---|---|
| Theilmann et al. (1994) Germany | Randomized controlled study | Palma stent | Aspirin (n = 21) VS. Control (n = 21) | 3 months |
| Sauer et al. (1996) Germany | Randomized controlled study | Palma stent | Phenprocoumon (n = 22) VS. Control (n = 23) | 3 months |
| Siegerstetter et al. (1997) Germany | Randomized controlled study | Wallstent、Palmazstent | Heparin (n = 12) VS. Control (n = 12) | 1 month |
| Wang et al. (2016) China | Randomized controlled study | Covered stent | Warfarin (n = 31) VS. Control (n = 33) | 12 months |
| Tang et al. (2017) China | Cohort study | Covered stent | Aspirin (n = 95)/Clopidogrel (n = 64)/Warfarin (n = 9) VS. Control (n = 14) | 6 months |
| Zhang et al. (2020) China | Cohort study | Covered stent | Warfarin (n = 27) VS. Control (n = 56) | 12–33 months |
| Lv et al. (2021) China | Cohort study | Covered stent | Warfarin/Heparin/Rivarsaban (n = 197) VS. Control (n = 88) | 21 months |
| Seifert et al. (2022) Germany | Cohort study | covered stents | Asprin (n = 150) VS. Control (n = 150) | Not mentioned |
| Han et al. (2011) China | Cohort study | Bare stent | Heparin-Warfarin-Aspirin (n = 43) | 6 months |
| Wang et al. (2015) China | Cohort study | Covered stent | Warfarin (n = 25) | 6 months |
| Lv et al. (2018) China | Randomized controlled study | Covered stent | Warfarin (n = 24) | 9.3 months |
| Wan et al. (2017) China | Cohort study | Covered and bare stents | Warfarin (n = 52)/Aspirin, Clopidogrel (n = 74) | 6 months |